Teva director granted 7,242 RSUs
Lichtenstein Chen reported acquisition or exercise transactions in this Form 4 filing.
Rhea-AI Filing Summary
Lichtenstein Chen reported acquisition or exercise transactions in this Form 4 filing.
TEVA PHARMACEUTICAL INDUSTRIES LTD director Lichtenstein Chen received a grant of 7,242 Restricted Share Units (RSUs). These RSUs were granted on May 28, 2026 and are scheduled to vest on May 28, 2027, functioning as part of equity-based compensation.
Each RSU represents a contingent right to receive, at settlement, either one ordinary share or the cash value of one ordinary share, at the option of the Human Resources and Compensation Committee. The ordinary shares may be represented by American Depositary Shares, with each ADS currently representing one ordinary share.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Share Units | 7,242 | $0.00 | $0.00 |
Footnotes (3)
- F1. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- F2. Restricted share units were granted on May 28, 2026 and vest on May 28, 2027.
- F3. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Key Figures
Key Terms
contingent right financial
equity-based compensation financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did TEVA (TEVA) director Lichtenstein Chen report in this Form 4?
What is the ownership position after this TEVA (TEVA) RSU grant?
AI-generated analysis. How Rhea-AI works. Not financial advice.